153 results about "Hepatoma cell" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention relates to the technical field of medical instruments, and provides a steep pulse-based ablation system and method for liver cancer cells, and the system comprises a tumor feature recognition module which is used for obtaining imaging images of the liver cancer cells and recognizing tumor features, blood supply conditions and tumor centers of the liver cancer cells; the electrode inlet setting module is used for setting a safety boundary of liver cancer cells and setting an ablation area and a focus skin surface of the liver cancer cells based on the safety boundary and tumor characteristics; the ablation effect analysis module is used for calculating the electrode depth and the electrode angle of the liver cancer cells and analyzing the coverage effect of an ablation area; the electric field intensity identification module is used for analyzing cell membrane characteristics of the hepatoma cells, identifying the electroporation effect of the hepatoma cells and identifying the electric field intensity of the hepatoma cells; and the steep pulse ablation module is used for performing ablation treatment on the liver cancer cells in combination with the electric field intensity and a pulse generator to obtain an ablation result. The invention aims to avoid heat injury of surrounding tissues and improve the ablation effect of liver cancer cells.

The invention relates to a gadolinium-doped carbon dot complex based on liver cancer cell membrane coating and a preparation method of the gadolinium-doped carbon dot complex. The gadolinium-doped carbon dot complex is prepared on the basis of gadolinium-doped carbon dots Gd-CDs which are prepared from indocyanine green, citric acid, polyethylene glycol and gadolinic acid through a one-step microwave thermal method and have fluorescence-magnetic resonance bimodal imaging capacity. The Gd-CDs complex Gd-CDs coated HCM is placed in a cell membrane suspension extracted from human hepatoma carcinoma cells HepG2, and the Gd-CDs complex Gd-CDs coated HCM which is uniform in particle size and has the capacity of photothermal and immunotherapy of hepatocellular carcinoma is obtained through extrusion construction of a liposome extruder. The Gd-CDs (at) HCM complex constructed by the invention not only has good bimodal imaging ability, but also has a specific inhibition effect on liver tumor cells, can be applied to preparation of drugs for inhibiting the growth of the liver tumor cells, and realizes a good treatment effect on liver cancer at a nanometer level.

The invention relates to the technical field of nano-drug presentation systems, in particular to a nanoparticle for synergistically promoting hepatoma ferroptosis based on mesoporous manganese dioxide, salazosulfapyridine and a tumor cell biological membrane as well as a preparation method and application of the nanoparticle. The nanoparticle in the scheme comprises mesoporous manganese dioxide which is modified with a tumor cell membrane on the surface and loaded with salazosulfapyridine. According to the technical scheme, the nanoparticles can effectively induce hepatoma cell ferroptosis through a multi-target strategy. The salazosulfapyridine and the mesoporous manganese dioxide have a synergistic effect to enhance the ferroptosis effect; the tumor cell biological membrane has homologous targeting property, so that the accumulation capacity of the nanoparticles in liver cancer tissues is remarkably improved; the nanoparticle provided by the invention not only can be used for treatment, but also can monitor the change in the treatment process in real time. According to the technical scheme, the technical problem that a nano-drug presentation system for effectively inducing ferroptosis aiming at multiple target spots is lacked in the prior art can be solved, and the technical scheme has important significance in improving the survival rate and the life quality of liver cancer patients.

The invention belongs to the field of microorganisms, and particularly relates to a pleurotus citrinopileatus strain for producing ergothioneine and a preparation method and application of ergothioneine. The pleurotus citrinopileatus strain is preserved in China General Microbiological Culture Collection Center (CGMCC). According to the preparation method of the ergothioneine, lactose and casein peptone are used as a carbon source and a nitrogen source of a liquid fermentation culture medium. The pleurotus citrinopileatus strain is used for high yield of ergothioneine, and the ergothioneine produced by fermentation is used for relieving oxidative stress damage of hepatoma carcinoma cells HepG2.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

The invention discloses a capsaicin compound and a preparation method and application thereof, the molecular formula of capsaicin Capsivaryine is C16H21NO3, the chemical structure of capsaicin Capsivaryine is as follows, and the capsaicin Capsivaryine compound is a new compound reported for the first time and is prepared by taking mature and dry fruits of capsicum as raw materials through crushing, sieving, silica gel column treatment, D101 macroporous resin treatment and HPLC (High Performance Liquid Chromatography). The compound disclosed by the invention has a certain in-vitro inhibition effect on human breast cancer cells MCF-7, human liver cancer cells HEPG2, human non-small cell lung cancer cells A549 and human ovarian cancer cells SKOV3, and has no toxicity on human normal liver cells L02. The compound is a natural product which is novel in structure and good in activity, has great potential in the anti-tumor aspect, enriches diversity of pepper plants, and provides guidance for research of chemical components of pepper. # imgabs0 #

The invention relates to a tumor hypoxia specific response BODIPY fluorescent probe as well as preparation and application thereof. The invention relates to a BODIPY fluorescent probe which is synthesized by utilizing tumor hypoxia to respond to azobenzene groups. The probe has no signal to normal oxygen cells, shows strong near-infrared fluorescence to hypoxia cancer cells, and can be used for visually detecting deep solid tumors. According to the present invention, the tumor specific response BODIPY fluorescent probe is adopted as the research object, the human liver cancer cells (HepG2) and the human non-small cell lung cancer cells (A549) are adopted as the tested cell strains, the fluorescence detection ability research under the normal oxygen and oxygen deficiency conditions is developed, and the foundation is established for the real-time accurate tumor detection. The fluorescent probe has the advantages of lower preparation cost, simpler synthesis method, easily available raw materials, less side reaction, high yield, easiness in purification, easiness in industrial production and the like.

The invention discloses a construction method of a large-scale liver cancer model co-cultured with immune cells, and relates to the technical field of liver cancer model construction. The method comprises the following steps: preparing primary hepatoma cells from in-vitro hepatoma tumor tissues, mixing the primary hepatoma cells with supporting hydrogel, refrigerating, and printing in a 12-pore plate to obtain a hepatoma printing body; placing the liver cancer printing body in a 100mM calcium chloride solution to quickly crosslink the liver cancer printing body, then culturing the liver cancer printing body by using a DMEM + 10% FBS culture medium, replacing a fresh culture medium every 2 days, and culturing for 5 days to obtain a large-scale liver cancer model; the CD8 + T cells and the large-scale liver cancer model are co-cultured for 48 h according to different proportions of 1: 1, 2: 1 and 5: 1, and the large-scale liver cancer model co-cultured with immune cells is obtained. The liver cancer model has the advantages of being uniform in size, stable in character, high in throughput and capable of easily reflecting cell activity. The model can reflect the effects of immunotherapy drugs such as PD1 and the like.

The invention discloses novel application of ganoderic acid B, belongs to the field of liver injury treatment, and particularly relates to application of ganoderic acid B in preparation of a medicine for treating liver cell injury caused by aflatoxin. According to the invention, human liver cancer HepG2 cells are utilized to construct an AFB1 cell injury model, lucid ganoderma active ingredients with a protection effect on injury are screened out, and the resistance mechanism of the lucid ganoderma active ingredients is researched and predicted, so that a new method and a new target spot are provided for searching for diseases caused by AFB1 prevention and treatment. A new method can be provided for preventing and treating the liver cancer caused by the AFB1.

The invention discloses application of chidamide in preparation of an anti-hepatoma drug synergist, and belongs to the technical field of medicines. According to the preparation for effectively improving the treatment effect of the anti-hepatoma medicine, chidamide serves as a sensitizer of the anti-tumor medicine, uptake of the anti-hepatoma medicine by hepatoma cells is promoted by up-regulating OATP1B3 protein expression in hepatoma tissue, accumulation of the medicine in the hepatoma tissue is increased, and therefore the anti-tumor effect of the medicine is improved. Combination of chidamide and the anti-liver cancer drug can synergistically enhance the toxicity of the drug to liver cancer, and the drug combination has biological safety and has great clinical application prospects.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-GPC3 monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The high-affinity anti-GPC3 sequence is obtained through screening, the binding specificity of the high-affinity anti-GPC3 sequence and the GPC3 antigen is high, and dissociation is slow. The sequence is used as an extracellular targeting domain to construct GPC3-CAR, after macrophages are transduced through lentivirus, CAR-M can specifically recognize GPC3 positive target cells, activate intracellular signal channels and remarkably improve in-vitro phagocytosis and killing activity, the hepatoma cell lysis effect is better, and technical support is provided for anti-hepatoma application.

The present invention relates to the technical field of anti-tumor compounds, and discloses an anti-tumor active compound, an extraction and separation method, a drug and uses thereof. The compound has a chemical structure of formula I, or a pharmaceutical composition of a pharmaceutically acceptable salt, stereoisomer, hydrate, solvate or prodrug of the compound of formula I. The present invention can extract and prepare an anti-tumor active compound from Leucosceptrum canum, and this compound has an inhibitory effect on human liver cancer cells.

The invention discloses application of sodium cantharidinate in preparation of a medicine for promoting CD3 + T cell proliferation, sodium cantharidinate acts on CD3 + T cells, proliferation of the CD3 + T cells can be promoted, human immunity can be effectively improved, and human lung cancer cells H460, human lung cancer cells A549 and human liver cancer cells HepG2 can be effectively killed.

The application relates to a synthesis method of red luminescent carbon dots with a targeting diagnosis and treatment potential of hepatocellular carcinoma, which comprises the following steps: 1) adding 5-fluorouracil and indocyanine green into deionized water, uniformly mixing, and forming a uniform mixed solution; 2) heating the mixed solution obtained in the step 1) at 160-200 DEG C for 5-9 h, and cooling to room temperature; 3) filtering and dialyzing the solution obtained in the step 2), and obtaining a pure 5-FICD solution; and 4) freeze-drying the solution obtained in the step 3), and obtaining the product. The method takes anticancer drug 5-fluorouracil and photosensitizer indocyanine green as precursors, synthesizes a low-toxicity red light carbon dot through a simple hydrothermal method, improves the shortcoming that a chemotherapy drug has a large side effect, and realizes the targeted killing of hepatocellular carcinoma cells.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

The application belongs to the technical field of biology and medicine, and discloses a PROTAC compound with a carbon chain as a connecting chain, which is developed based on a PROTAC technology, and a structural general formula of the PROTAC compound is formula 1: wherein R is -(CH2) n -, and n is 3-8. The synthesized PROTAC compound is a new compound, has a TG content reducing activity in a high-fat model established by L02 and HepG2, and has a low-toxicity activity in human hepatoma cells HepG2, human normal liver cells L02 and human umbilical vein endothelial cells HUVEC compared with a warhead. The synthesized PROTAC compound is a new type of anti-non-alcoholic fatty liver disease drug with low toxicity and high efficiency. The application of the PROTAC technology is widened while developing an efficient treatment of anti-non-alcoholic fatty liver disease.

The present invention discloses a compound with structural formula I. The compound of the present invention exhibits strong inhibitory activity against Mycobacterium tuberculosis, has good antituberculosis effects, and has a significantly reduced MIC value compared with isoniazid, a first-line clinical drug. It has weak inhibitory effects on the proliferation of human hepatoma cells HepG2 and Chang cells and has good safety. In addition, in the experiment of Mycobacterium tuberculosis infection overexpressing DprE1, the antibacterial ability of the compound decreased, further verifying that the compound exerts its antibacterial effect by inhibiting the DprE1 enzyme, and it is a novel DprE1 inhibitor.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention discloses a cynanchum atratum extract as well as a preparation method and application thereof. The cynanchum atratum extract is an extract obtained by extracting cynanchum atratum with 50-80% ethanol. The cynanchum atratum is a root and a rhizome of a Tylophora yunnanensis Schlechter, which is a plant of the Schlechter family, and the root and the rhizome of the Tylophora yunnanensis Schlechter. Cell experiments and animal experiments prove that the extract obtained by extracting cynanchum atratum with 75% ethanol has the effects of inhibiting breast cancer and hepatoma carcinoma cell proliferation, inducing breast cancer and hepatoma carcinoma cell death and reducing tumor volume and tumor quality, has a remarkable effect on treating liver cancer and breast cancer, and has a practical application value.

The invention belongs to the field of biological medicine, and particularly relates to siRNA for inhibiting INHBE gene expression and a conjugate and application thereof. According to the present invention, the corresponding siRNA is designed according to the INHBE gene, and the siRNA is delivered to the liver by coupling GalNAc so as to interfere the INHBE mRNA at the liver position, such that the expression of the INHBE protein can be effectively reduced, the healthy fat storage can be promoted, and the obesity treatment effect can be further achieved. The siRNA and the siRNA conjugate provided by the invention can be used for remarkably inhibiting proliferation of human liver cancer cells Hep-G2, and have an effect on inhibiting mouse liver INHBE mRNA, so that the siRNA and the siRNA conjugate provided by the invention have a good prospect in application of obesity.

The invention belongs to the technical field of molecular biology and medicine, and particularly relates to application of lncRNA TUG1 serving as a target spot to preparation of a medicine for treating metabolism-related fatty liver diseases. According to the application disclosed by the invention, it is found that lncRNA TUG1 can be knocked down in a targeted manner by transfecting siRNA in human hepatoma carcinoma cells HepG2, so that the expression of the lncRNA TUG1 is reduced, and the contents of total cholesterol, free cholesterol and triglyceride are remarkably reduced; meanwhile, the mouse hepatoma carcinoma cell Hepa1-6 is transfected with siRNA to knock down lncRNA TUG1, so that the expression of the mouse hepatoma carcinoma cell Hepa1-6 is reduced. Besides, an MAFLD animal model is established, and it is found that compared with a control group, the expression of lncRNA TUG1 in the mouse liver of the model group is remarkably improved. The results indicate that the lncRNA TUG1 possibly becomes a new target for developing MAFLD related drugs, and it is clear that the lncRNA TUG1 affects generation of fat and cholesterol to achieve treatment intervention on MAFLD.

This invention discloses a method for preparing fucoidan from *Sargassum hemifolia* and its application in the preparation of anti-hepatocellular carcinoma drugs. Experimental results show that *Sargassum hemifolia* fucoidan Fb has a strong inhibitory effect on HepG2 hepatocellular carcinoma cells, significantly stronger than the inhibitory effects of *Sargassum henryi* polysaccharide Fh and *Sargassum fusiforme* polysaccharide SFPS on HepG2 hepatocellular carcinoma cells. After treatment of HepG2 hepatocellular carcinoma cells with *Sargassum hemifolia* fucoidan DF1 and DF2, apoptosis is ultimately induced through the interaction and cooperation of exogenous (death receptor pathway) and endogenous (mitochondrial pathway). *Sargassum hemifolia* fucoidan possesses strong antitumor activity and therefore can be used to prepare anti-hepatocellular carcinoma drugs.

The invention provides an application of a compound WAY-226570 in preparation of an anti-liver cancer drug. The invention firstly finds that WAY-226570 (the molecular formula is C14H10F3N3) can inhibit the proliferation effect and migration and invasion activity of liver cancer cells, and further, the lenvatinib and WAY-226570 are combined to generate a synergistic inhibition effect on the proliferation of the liver cancer cells, so that the lenvatinib can be used as a combined medicine composition to be applied to the preparation of the medicine for preventing and / or treating the liver cancer, and has a clinical application prospect.

This invention discloses a nanoparticle-based drug delivery system, MPL@ICC, its synthesis method, and its applications. The MPL@ICC system consists of hollow, porous nano-MnO2, a hydrophilic targeting complex on its surface, and an acid-responsive drug, INH-CA, and a photosensitizer loaded internally. It possesses both targeted transport and controlled release capabilities against human hepatocellular carcinoma cells (HepG2), allowing it to accumulate within these cells and achieve photodynamic therapy (PDT) and free radical-induced immune killing within the tumor. Simultaneously, it directly kills tumor cells and transforms them from non-immunogenic to immunogenic, mediating an anti-tumor immune response and achieving immunogenic cell death (ICD). This overcomes the shortcomings of ICD-induced cancer treatment strategies, which often fail to produce strong and durable therapeutic effects, and does not induce normal cell apoptosis, thus possessing controllability, effectiveness, and safety.

The invention relates to a drug combination of annona squamosa lactone compounds and sorafenib (SF), which is characterized in that four common human hepatoma cell lines HepG2, HuH7, MHCC97H and HCCLM3 are used as research objects, and the drug combination effect among different components is evaluated by using an MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 3-diphenyltetrazolium bromide) method and Synergy Finder software. The combination of the compound and SF shows an obvious synergistic inhibition effect on the growth of hepatoma carcinoma cells, and meanwhile, the pharmaceutical composition can synergistically reduce the ATP level of the hepatoma carcinoma cells and induce hepatoma carcinoma cell apoptosis. Pharmacodynamic experiments show that the compounds annonacin and SF can synergistically inhibit tumor growth and induce tumor cell apoptosis, and have no obvious toxicity to normal organs of nude mice at a low dosage. In addition, transcriptome analysis predicts that the anti-liver cancer target of the annonacin is possibly related to the SLC33A1 gene. The method can be used for preparing anti-hepatoma drugs and researching related mechanisms. The annona lactone compound disclosed by the invention is derived from annona montana Macf. Which is an annona plant, namely annona montana Macf.

This invention discloses a mixed hepatocyte terahertz quantitative detection system, electronic device, and medium, comprising: a spectral preprocessing module for acquiring a mixed hepatocyte time-domain spectrum and converting it into a mixed hepatocyte terahertz frequency-domain spectrum using a fast Fourier transform; calculating the refractive index and absorption coefficient to obtain frequency-domain signals of the refractive index and absorption coefficient, and processing them using Gram angle sum field and Gram angle difference field to obtain Gram angle sum field map and Gram angle difference field map; an image feature extraction module for extracting gradient features from the Gram angle sum field map and Gram angle difference field map using gradient histograms; extracting grayscale features from the Gram angle sum field map and Gram angle difference field map using grayscale histograms; fusing the gradient features and grayscale features to obtain image features; and a hepatocyte cancer cell content quantitative detection module for inputting the image features into a pre-trained hepatocyte cancer cell content quantitative detection model to obtain the proportion of hepatocyte cancer cells.

A method for inhibiting expression of receptor tyrosine kinase EPHA2, which comprises inhibiting expression of receptor tyrosine kinase EPHA2 of tumor cells by regulating expression of a ubiquitin ligase RNF114, and the mode of regulating the ubiquitin ligase RNF114 comprises knocking down expression level of RNF114 protein by RNA interference technology, or knocking out RNF114 protein expression gene by CRISPR / Cas9 method. The present application uses biochemical and tumor molecular biology means to study ubiquitination of receptor tyrosine kinase EPHA2 regulated by ubiquitin ligase RNF114 and its role in proliferation and migration of hepatocarcinoma cells. Meanwhile, the present application effectively knocks down or knocks out expression of RNF114 in hepatocarcinoma cells by designing specific siRNA, shRNA and sgRNA, and finds that the proliferation and migration ability of hepatocarcinoma cells can be effectively inhibited.